sabatolimab   Click here for help

GtoPdb Ligand ID: 12361

Synonyms: MBG-453 | MBG453
Compound class: Antibody
Comment: Sabatolimab (MBG-453) is an anti-TIM3 (HAVCR2) monoclonal antibody [1-2], that was developed as a leukemia immunotherapy. It binds to TIM3 on myeloid cells, blocking the interaction between TIM3 and its endogenous ligands PtdSer/galectin 9. This action blocks TIM3's function as an immune co-inhibitory receptor, and promotes an immune response against neoplastic myeloid cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Sabatolimab (MBG-453) has advanced to late stage clinical evaluation to determine effecacy against high risk myelodysplastic syndromes.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04150029 A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy Phase 2 Interventional Novartis
NCT03946670 A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). Phase 2 Interventional Novartis
NCT04266301 Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Phase 3 Interventional Novartis